The Telix Pharmaceuticals Limited (TLPPF) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory submissions, with AI-powered tools to help interpret them. Telix Pharmaceuticals Limited is a foreign private issuer that furnishes current reports on Form 6-K and indicates that it files annual reports on Form 20-F. These filings connect U.S. investors to announcements first made to the Australian Securities Exchange.
Each Form 6-K cover page identifies an attached announcement or press release, typically labeled as Exhibit 99.1. Examples include “Telix JP Morgan Healthcare Conference 2026 Presentation,” “Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions,” “ProstACT Global Study Status,” “1st Patient Dosed in ProstACT Global Randomized Tx Expansion,” “Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded,” and “CMS Grants Transitional Pass-Through Status for Gozellix.” The detailed content is contained in the exhibits, while the Form 6-K itself confirms the nature and title of each disclosure.
On this page, you can review Telix’s Form 6-K submissions as they appear in the SEC’s EDGAR system, with real-time updates as new filings are furnished. AI-generated summaries highlight the key points of lengthy documents, helping you quickly understand the focus of each announcement. You can also use this page to locate Telix Pharmaceuticals Limited’s annual Form 20-F filings when available, giving you a structured way to examine both periodic and event-driven disclosures associated with the TLPPF symbol.
Telix Pharmaceuticals Ltd MD & Group CEO Dr. Christian Behrenbruch, through Elk River Holdings Pty Ltd, made two open-market purchases of Ordinary Shares. On April 28 and 29, he indirectly bought a combined 67,935 shares at average prices around $14.48 and $14.87 per share, reported in Australian Dollars. After these transactions, his indirect holdings rose to 20,742,935 Ordinary Shares. The filing notes that the reported prices are volume-weighted averages for multiple trades within specified price ranges.
Telix Pharmaceuticals Ltd MD & Group CEO Dr. Christian Behrenbruch, through Elk River Holdings Pty Ltd, made two open-market purchases of Ordinary Shares. On April 28 and 29, he indirectly bought a combined 67,935 shares at average prices around $14.48 and $14.87 per share, reported in Australian Dollars. After these transactions, his indirect holdings rose to 20,742,935 Ordinary Shares. The filing notes that the reported prices are volume-weighted averages for multiple trades within specified price ranges.
Telix Pharmaceuticals Limited, a foreign private issuer, submitted a Form 6-K relating to its shareholder meeting materials. On April 21, 2026 in Melbourne, the company lodged with the Australian Securities Exchange an announcement titled “Telix Notice of AGM, Proxy Form and Online Guide,” which is furnished to U.S. investors as Exhibit 99.1.
Telix Pharmaceuticals Limited, a foreign private issuer, submitted a Form 6-K relating to its shareholder meeting materials. On April 21, 2026 in Melbourne, the company lodged with the Australian Securities Exchange an announcement titled “Telix Notice of AGM, Proxy Form and Online Guide,” which is furnished to U.S. investors as Exhibit 99.1.
Telix Pharmaceuticals Limited has priced and upsized a US$600 million Offering of 1.50% convertible bonds due on or about 22 April 2031, issued by its U.S. subsidiary and guaranteed by Telix and a U.S. affiliate. The Convertible Bonds are convertible into Telix ordinary shares at an initial conversion price of US$13.85 (~A$19.55) per share, a 37.5% premium to a A$14.22 reference share price. Telix will concurrently repurchase approximately A$637 million of its existing A$650 million convertible bonds due 2029, with the balance intended to be redeemed, materially extending its debt maturity profile. Settlement of the new Offering and the Concurrent Repurchase is expected on 22 April 2026, subject to customary conditions, and is supported by a stock borrow facility over 15 million shares for 11 months.
Telix Pharmaceuticals Limited has priced and upsized a US$600 million Offering of 1.50% convertible bonds due on or about 22 April 2031, issued by its U.S. subsidiary and guaranteed by Telix and a U.S. affiliate. The Convertible Bonds are convertible into Telix ordinary shares at an initial conversion price of US$13.85 (~A$19.55) per share, a 37.5% premium to a A$14.22 reference share price. Telix will concurrently repurchase approximately A$637 million of its existing A$650 million convertible bonds due 2029, with the balance intended to be redeemed, materially extending its debt maturity profile. Settlement of the new Offering and the Concurrent Repurchase is expected on 22 April 2026, subject to customary conditions, and is supported by a stock borrow facility over 15 million shares for 11 months.
Telix Pharmaceuticals is launching an offering of US$550 million convertible notes due 2031 through a wholly owned subsidiary, guaranteed by Telix entities, to refinance its existing 2029 convertible bonds and fund general corporate purposes. The notes carry an expected coupon of 1.50–1.75% and a 35–37.5% conversion premium, with a 5‑year maturity and an investor put after year three.
The company also highlights strong recent performance, with 2025 group revenue of US$804 million, up 56% year over year, including US$622 million from Precision Medicine and US$40 million EBITDA. Q1 2026 revenue reached US$230 million, up 11% sequentially, and 2026 revenue guidance is US$950–970 million. Telix outlines a late‑stage radiopharma pipeline, near‑term regulatory milestones and a new collaboration with Regeneron that includes US$40 million upfront and up to US$2.1 billion in potential milestones.
Telix Pharmaceuticals is launching an offering of US$550 million convertible notes due 2031 through a wholly owned subsidiary, guaranteed by Telix entities, to refinance its existing 2029 convertible bonds and fund general corporate purposes. The notes carry an expected coupon of 1.50–1.75% and a 35–37.5% conversion premium, with a 5‑year maturity and an investor put after year three.
The company also highlights strong recent performance, with 2025 group revenue of US$804 million, up 56% year over year, including US$622 million from Precision Medicine and US$40 million EBITDA. Q1 2026 revenue reached US$230 million, up 11% sequentially, and 2026 revenue guidance is US$950–970 million. Telix outlines a late‑stage radiopharma pipeline, near‑term regulatory milestones and a new collaboration with Regeneron that includes US$40 million upfront and up to US$2.1 billion in potential milestones.
Telix Pharmaceuticals reports that the U.S. FDA has accepted its resubmitted New Drug Application for TLX101-Px (Pixclara), a PET imaging agent for glioma, and has assigned a PDUFA goal date of September 11, 2026.
TLX101-Px has Orphan Drug and Fast Track designations and is intended to help distinguish recurrent or progressive glioma from treatment-related changes in adults and children. Telix notes that its FY 2026 financial guidance does not include any revenue from TLX101-Px.
Telix Pharmaceuticals reports that the U.S. FDA has accepted its resubmitted New Drug Application for TLX101-Px (Pixclara), a PET imaging agent for glioma, and has assigned a PDUFA goal date of September 11, 2026.
TLX101-Px has Orphan Drug and Fast Track designations and is intended to help distinguish recurrent or progressive glioma from treatment-related changes in adults and children. Telix notes that its FY 2026 financial guidance does not include any revenue from TLX101-Px.
Telix Pharmaceuticals Limited has expanded its Board by appointing two additional Non-Executive Directors, effective May 11, 2026, as part of broader succession planning. Maria Rivas, MD brings more than 25 years of experience in late-stage clinical development and commercialization, including service as Chief Medical Officer at Pfizer.
William (Bill) Jellison adds over 30 years of corporate finance and audit committee leadership, having served as Vice President and CFO of Stryker and as a director for multiple U.S. public companies. Telix’s Interim Chair said these appointments support the company’s evolution as a dual-listed, global, commercial-stage biopharmaceutical business focused on radiopharmaceuticals for oncology and rare diseases.
Telix Pharmaceuticals Limited has expanded its Board by appointing two additional Non-Executive Directors, effective May 11, 2026, as part of broader succession planning. Maria Rivas, MD brings more than 25 years of experience in late-stage clinical development and commercialization, including service as Chief Medical Officer at Pfizer.
William (Bill) Jellison adds over 30 years of corporate finance and audit committee leadership, having served as Vice President and CFO of Stryker and as a director for multiple U.S. public companies. Telix’s Interim Chair said these appointments support the company’s evolution as a dual-listed, global, commercial-stage biopharmaceutical business focused on radiopharmaceuticals for oncology and rare diseases.
Telix Pharmaceuticals reports strong first-quarter momentum, with unaudited Q1 2026 group revenue of US$230 million, up 24% year-over-year and 11% from Q4 2025. Precision Medicine revenue reached US$186 million, rising 23% year-over-year as Illuccix and Gozellix dose volumes and market share increased.
The company reaffirmed its FY 2026 revenue guidance of US$950–970 million and R&D expenditure guidance of US$200–240 million, indicating continued heavy investment in its pipeline. TMS third-party revenue was US$44 million, up 29% year-over-year.
Telix highlighted multiple late-stage pipeline advances, including Part 1 of the global Phase 3 ProstACT trial for TLX591-Tx meeting safety and dosimetry objectives with no new safety signals, first-patient-in for pivotal trials in brain cancer and glioblastoma, and regulatory progress for imaging agents TLX101-Px (NDA resubmission in the U.S. and MAA filing in Europe) and TLX250-Px (preparing a BLA resubmission after successful FDA Type A meetings). Corporate updates include appointing David Gill as a new Non-Executive Director, with an expectation he will become Chair.
Telix Pharmaceuticals reports strong first-quarter momentum, with unaudited Q1 2026 group revenue of US$230 million, up 24% year-over-year and 11% from Q4 2025. Precision Medicine revenue reached US$186 million, rising 23% year-over-year as Illuccix and Gozellix dose volumes and market share increased.
The company reaffirmed its FY 2026 revenue guidance of US$950–970 million and R&D expenditure guidance of US$200–240 million, indicating continued heavy investment in its pipeline. TMS third-party revenue was US$44 million, up 29% year-over-year.
Telix highlighted multiple late-stage pipeline advances, including Part 1 of the global Phase 3 ProstACT trial for TLX591-Tx meeting safety and dosimetry objectives with no new safety signals, first-patient-in for pivotal trials in brain cancer and glioblastoma, and regulatory progress for imaging agents TLX101-Px (NDA resubmission in the U.S. and MAA filing in Europe) and TLX250-Px (preparing a BLA resubmission after successful FDA Type A meetings). Corporate updates include appointing David Gill as a new Non-Executive Director, with an expectation he will become Chair.
Telix Pharmaceuticals Limited has appointed experienced life sciences executive David Gill as a Non-Executive Director as part of its board expansion and succession planning. His appointment is effective May 11, 2026, subject to grant of an Australian Director Identification number.
Gill is expected to become Chair in due course, succeeding Interim Chair Dr. Mark Nelson, who will remain on the board as a Non-Executive Director. Telix also announced that Genevieve Ryan resigned as Company Secretary effective April 2, 2026, with Shomalin Naidoo appointed interim Company Secretary and primary ASX Listing Rule contact from the same date.
Telix Pharmaceuticals Limited has appointed experienced life sciences executive David Gill as a Non-Executive Director as part of its board expansion and succession planning. His appointment is effective May 11, 2026, subject to grant of an Australian Director Identification number.
Gill is expected to become Chair in due course, succeeding Interim Chair Dr. Mark Nelson, who will remain on the board as a Non-Executive Director. Telix also announced that Genevieve Ryan resigned as Company Secretary effective April 2, 2026, with Shomalin Naidoo appointed interim Company Secretary and primary ASX Listing Rule contact from the same date.